Letters to the Editor

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low or intermediate-1 risk myelodysplastic syndrome

Malignant Hematology Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University Dusseldorf, Universitätsklinikum, Dusseldorf
NCT/UCC-ECTU, Medical Faculty Carl Gustav Carus, Technical University, Dresden
Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss
Department of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL
Haematologica Early view Jun 23, 2022 https://doi.org/10.3324/haematol.2021.280500